报价延迟最少15分钟:2026/06/06 01:58 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.63 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-8.29/-0.44
|
|
企业价值
19.05M
|
| 资产负债 |
|
每股账面净值
0.80
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
54.23K
|
|
每股收益
0.53
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class ofdrugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discoveryand development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment. |
